Tenderwize
Retour à la recherche

Discount Agreement for Choriongonadotropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 277 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-10 - Choriongonadotropin alfa

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products containing Choriongonadotropin alfa to patients insured by TK, HEK, and hkk.
  • Conclusion of a discount agreement under § 130a Abs. 8 SGB V with uniform terms for all participating pharmaceutical entrepreneurs.
Afficher le résumé complet

This is an Open House procedure by Techniker Krankenkasse (TK) and associated health insurers for discount agreements on the active substance Choriongonadotropin alfa. The contract is open to all qualified pharmaceutical entrepreneurs under uniform terms, with no exclusivity. The maximum contract duration is 24 months from June 1, 2025 to May 31, 2027. Submissions can be made at any time during the period, but must be submitted via email with qualified electronic signature or by post. The estimated contract value is not provided. The notice clarifies this is not a public procurement procedure under EU directives; legal challenges fall under social courts.

Risques

No estimated value or framework maximum is provided. Bidders cannot assess potential revenue or pricing strategy.

Since all qualified applicants can participate, many competitors may join, potentially limiting market share for each c...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG for the offered medicinal product.
  • Must have a registered office in Germany, another EU member state, or a EEA state (§ 9 Abs. 2 Satz 1 AMG).
  • Must hold a valid marketing authorisation for the relevant medicinal product or be otherwise entitled to place it on the market.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Discount Agreement for Choriongonadotropin alfa

Open House procedure for concluding discount agreements with all suitable pharmaceutical entrepreneurs for the active substance Choriongonadotropin alfa. Uniform terms apply; no exclusivity is granted.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; contracts are offered to all qualified pharma entrepreneurs.

Date limite

Deadline May 30, 2027

Détails de la procédure

Date de publication
22 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
262953-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3